| June 2, 2022 |
Attention Provider Type 28 (Pharmacy): Vaccine Administration Incentive for Expanded Use of Pfizer BioNTech COVID-19 Vaccine Booster Dose for Children 5 through 11 |
| May 4, 2022 |
Attention Provider Type 28 (Pharmacy): Additional Details Regarding Nevada Medicaid Fee-for-Service Transition of Pharmacy Benefits Management to Magellan Medicaid Administration Inc. on July 1, 2022 |
| April 20, 2022 |
Attention Provider Type 28 (Pharmacy): Claims Impacted by Pricing Load Issue will be Reprocessed |
| April 14, 2022 |
Attention Provider Type 28 (Pharmacy): Nevada Medicaid Fee-for-Service Transition of Pharmacy Benefits Management to Magellan Medicaid Administration Inc. on July 1, 2022 |
| April 14, 2022 |
Attention Provider Type 28 (Pharmacy): Second COVID-19 Vaccine Booster Dose |
| March 31, 2022 |
Drug Use Review (DUR) Board Approves Changes Effective March 21, 2022 |
| March 11, 2022 |
Prior Authorization for Non-Hospice Related Drugs for Recipients on Hospice |
| Feb. 8, 2022 |
Attention Provider Type 28 (Pharmacy): IN-HOME COVID-19 Vaccine Administration Provider Incentive Adjusted |
| Feb. 8, 2022 |
Attention Provider Type 28 (Pharmacy): COVID-19 Vaccine Administration Provider Incentive Fee Adjusted |
| Feb. 8, 2022 |
Attention Provider Type 28 (Pharmacy): Expanded Use for the Pfizer BioNTech COVID-19 Vaccine |
| Jan. 28, 2022 |
Attention Provider Type 28 (Pharmacy): Nevada Medicaid Fee-for-Service (FFS) Update Regarding COVID-19 Oral Antivirals Reimbursement |
| Jan. 20, 2022 |
Attention Provider Type 28 (Pharmacy): Pfizer-BioNTech COVID-19 Vaccine for Individuals 16 and 17 Years of Age |
| Jan. 14, 2022 |
Attention Provider Type 28 (Pharmacy): Camphotrex™ Gel Requires Prior Authorization Effective January 12, 2022 |
| Jan. 3, 2022 |
Updated Medicare Part D Benefit Co-Pay for 2022 |
| Dec. 14, 2021 |
Attention Provider Type 28 (Pharmacy): In-Home COVID-19 Vaccination Administration (Updated December 28, 2021) |
| Dec. 3, 2021 |
Attention Provider Type 28 (Pharmacy): Folite Requires Prior Authorization Effective December 1, 2021 |
| Dec. 3, 2021 |
Attention Provider Type 28 (Pharmacy): FDA Expands Eligibility for COVID-19 Vaccine Boosters |
| Nov. 18, 2021 |
Attention Provider Type 28 (Pharmacy): COVID-19 Pfizer, Moderna and Janssen Booster Dose |
| Nov. 17, 2021 |
Attention Provider Type 28 (Pharmacy): Emergency Use Authorization for Pfizer-BioNTech COVID-19 Vaccine for Children 5 through 11 Years of Age |
| Nov. 1, 2021 |
Drug Use Review (DUR) Board Approves Changes Effective November 1, 2021 |
| Sept. 20, 2021 |
Attention Provider Type 28 (Pharmacy): Reimbursement for Additional Doses of Moderna and Pfizer COVID-19 Vaccines |
| Sept. 7, 2021 |
Attention Provider Type 28 (Pharmacy): Guidance on Pharmacies Filling Prescriptions Under Declaration of Emergency Due to Caldor Fire |
| Sept. 1, 2021 |
Nevada Medicaid Expands Dates for 2021-2022 Respiratory Syncytial Virus (RSV) Season |
| Aug. 31, 2021 |
Drug Use Review (DUR) Board Approves Changes Effective September 1, 2021 |
| Aug. 25, 2021 |
U.S. Food and Drug Administration Approves First COVID-19 Vaccine |
| Aug. 20, 2021 |
Attention Provider Type 28 (Pharmacy): Amendment to Vaccine Administration Reimbursement for Additional Doses of Moderna and Pfizer COVID-19 Vaccines |
| Aug. 13, 2021 |
Provider Billing Guidance for Synagis® (Palivizumab) (Updated September 1, 2021) |
| July 6, 2021 |
Drug Use Review (DUR) Board Approves Changes Effective July 6, 2021 |
| June 1, 2021 |
Attention Prescribers and Pharmacies: Nevada Medicaid Fee-for-Service Updates for Insulin Syringes |
| May 24, 2021 |
Attention Provider Type 28 (Pharmacy): Nevada Medicaid Fee-for-Service Update Regarding COVID-19 Vaccine Administration Reimbursement (Updated May 24, 2021) |
| April 6, 2021 |
Drug Use Review (DUR) Board Approves Changes Effective March 1, 2021 |
| March 31, 2021 |
Prior Authorization Process for Zolgensma® (onasemnogene abeparvovec-xioi) for Fee-for-Service and Managed Care Organization Recipients |
| March 23, 2021 |
OptumRx Prior Authorization Process for Obtaining Additional Information |
| March 22, 2021 |
OptumRx Pharmacy Benefits Manager System Updates |
| Dec. 28, 2020 |
Updated Medicare Part D Benefit Co-Pay for 2021 |
| Dec. 21, 2020 |
New Pharmacy Electronic Prior Authorization (ePA) System Implemented |
| Nov. 30, 2020 |
Drug Use Review (DUR) Board Approves Changes Effective November 30, 2020 |
| Nov. 25, 2020 |
Urgent: Nevada Medicaid Pharmacy Services Issues Stop Coverage on Folixapure™ Effective November 25, 2020 |
| Oct. 13, 2020 |
Respiratory Syncytial Virus (RSV) Prophylaxis with Synagis® (Palivizumab) |
| Oct. 2, 2020 |
Prescription Drug Coverage for Medication Assisted Treatment (MAT) Update |
| Sept. 24, 2020 |
Prescription Drug Coverage for Medication Assisted Treatment (MAT) (Updated October 2, 2020) |
| Sept. 21, 2020 |
Pharmacy Claims for Schedule II Drugs to Require Quantity Authorized by Prescriber |
| Aug. 31, 2020 |
Drug Use Review (DUR) Board Approves Changes Effective August 31, 2020 |
| Aug. 28, 2020 |
DHCFP Issues Stop Coverage on Non-Rebate Products Effective August 28, 2020 |
| Aug. 28, 2020 |
Addition of OneTouch® Blood Glucose Meter to Preferred Nevada Medicaid Diabetic Supply Program |
| Aug. 24, 2020 |
Urgent: Nevada Medicaid Pharmacy Services Issues Stop Coverage on Empricaine Kit II Effective August 21, 2020 |
| Aug. 21, 2020 |
Attention Prescribers and Pharmacies: Emergency Regulation Restricting Prescribing and Dispensing of Hydroxychloroquine and Chloroquine during Novel Coronavirus (COVID-19) Pandemic Has Expired |
| Aug. 17, 2020 |
Billing Instructions for Pharmacy Point of Sale (POS) Claims Exceeding $999,999.99 |
| Aug. 3, 2020 |
Drug Use Review (DUR) Board Approves Changes Effective August 3, 2020 |
| July 17, 2020 |
Urgent: Nevada Medicaid Pharmacy Services Issues Stop Coverage on DermacinRx Products Effective July 17, 2020 |
| May 14, 2020 |
Remdesivir Authorized for Novel Coronavirus (COVID-19) Treatment (Updated June 19, 2020) |
| May 4, 2020 |
Attention Pharmacies: Override on Restriction for Contraceptives During Postpartum Period |
| April 3, 2020 |
Attention Prescribers and Pharmacies: Temporary Prior Authorization Override to Allow Compounding of Certain Alcohol-Based Hand Sanitizer Products during Novel Coronavirus (COVID-19) Pandemic |
| March 27, 2020 |
Attention End Stage Renal Disease (ESRD) Facilities: Pharmaceuticals Included in Prospective Payment System (PPS) |
| March 25, 2020 |
Attention Prescribers and Pharmacies: Emergency Regulation on Prescribing and Dispensing Hydroxychloroquine and Chloroquine during Novel Coronavirus (COVID-19) Pandemic |
| March 20, 2020 |
Attention Prescribers and Pharmacies: Hydroxychloroquine and Chloroquine Diagnosis Requirements on Prescriptions and Guidance for Treatment of Novel Coronavirus (COVID-19) (Updated March 24, 2020) |
| March 17, 2020 |
CPT Code 90686 (Fluarix®) is FDA-Approved and is a Vaccine for Children (VFC) Vaccine |
| March 17, 2020 |
Pharmacy “Refill Too Soon Waiver” Implemented in Response to Coronavirus Disease (COVID-19) Threat |
| March 3, 2020 |
Updated Details Regarding Diabetic Supply Policy Changes |
| Feb. 28, 2020 |
Drug Use Review (DUR) Board Approves Changes Effective March 2, 2020 |
| Feb. 27, 2020 |
DHCFP to Host Diabetic Supply Preferred Product Educational Webinar |
| Feb. 6, 2020 |
Updates to Diabetic Supply Policy Changes |
| Dec. 30, 2019 |
Diabetic Supply Policy Changes for Nevada Medicaid |
| Dec. 23, 2019 |
Medicare Part D Co-Pay Reimbursement Increase for 2020 |
| Dec. 12, 2019 |
Medicaid Services Manual Chapter 1200 - Prescribed Drugs Updates |
| Dec. 4, 2019 |
Diabetic Supply Policy Changes for Nevada Medicaid |
| Dec. 2, 2019 |
Drug Use Review (DUR) Board Approves Changes Effective December 2, 2019 |
| Nov. 15, 2019 |
Brand Voltaren® Gel Unavailable |
| Nov. 14, 2019 |
Diabetic Supply Policy Changes for Nevada Medicaid |
| Oct. 7, 2019 |
Respiratory Syncytial Virus (RSV) Prophylaxis with Synagis® (Palivizumab) |
| September 24, 2019 |
Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (SUPPORT Act) Compliance |
| September 10, 2019 |
Urgent: Physician-Administered Drug (PAD) Claim Processing |
| September 3, 2019 |
Drug Use Review (DUR) Board Approves Changes Effective September 2, 2019 |
| July 25, 2019 |
Update to Compounded Medications Prior Authorization Requirement |
| June 12, 2019 |
Compounded Medications Require Prior Authorization Effective June 3, 2019 |
| June 12, 2019 |
New and Updated Pharmacy Prior Authorization Forms |
| May 31, 2019 |
Drug Use Review (DUR) Board Approves Changes Effective June 3, 2019 |
| May 6, 2019 |
Nevada Medicaid Human Papillomavirus (HPV) Vaccine Policy Effective May 6, 2019 |
| March 15, 2019 |
Drug Use Review (DUR) Board Approves Changes Effective February 4, 2019 |
| March 14, 2019 |
Nevada Medicaid Drug Use Review Board Votes to Adopt Policy on Outpatient Antibiotic Medications |
| Dec. 10, 2018 |
Medicare Part D Co-Pay Reimbursement Increase |
| Nov. 8, 2018 |
DHCFP to Host Antibiotic Policy & Provider Education Webinar (Updated December 6, 2018) |
| Oct. 25, 2018 |
Respiratory Syncytial Virus (RSV) Prophylaxis with Synagis® (Palivizumab) |
| Sept. 10, 2018 |
Drug Use Review (DUR) Board Approves Changes Effective July 2, 2018 |
| Aug. 6, 2018 |
Drug Use Review (DUR) Board Approves Changes Effective August 6, 2018 |
| June 21, 2018 |
Pharmacy Announcement: Prior Authorization for High Dollar Claims will be Implemented August 6, 2018 |
| June 20, 2018 |
Drug Use Review (DUR) Board Approves Changes Effective May 7, 2018 |
| May 7, 2018 |
Prior Authorization Required for Mavyret™ and Vosevi® |
| Feb. 2, 2018 |
Drug Use Review (DUR) Board Approves Change Effective February 5, 2018 |
| Jan. 2, 2018 |
Medicare Part-D Co-Pay Change |
| Dec. 29, 2017 |
Drug Use Review (DUR) Board Approves Changes Effective January 1, 2018 |
| Dec. 22, 2017 |
Coverage Requirements for Contraceptive Drugs, Devices and Services to Implement on January 1, 2018 |
| Oct. 6, 2017 |
Respiratory Syncytial Virus (RSV) Prophylaxis with Synagis® (Palivizumab) |
| Oct. 6, 2017 |
Insulin Quantity Limit Adjusted to Allow 65 to 120 Day Supply |
| Oct. 2, 2017 |
Legislative Assembly Bill AB473 Extends NRS 422.4025 Sunset until June 30, 2019 |
| July 31, 2017 |
Drug Use Review (DUR) Board Approves Changes Effective August 1, 2017 |
| May 5, 2017 |
Criteria for Practitioners to Dispense Medications |
| May 2, 2017 |
Drug Use Review (DUR) Board Approves Changes to MSM Chapter 1200 |
| May 1, 2017 |
Quantity Limits Approved at January 2017 Drug Use Review Board Meeting |
| March 30, 2017 |
Opioid Therapeutic Class to be Added to Medicaid Services Manual (MSM) Chapter 1200 (Prescribed Drugs) (Updated April 28, 2017) |
| Feb. 23, 2017 |
Attention Prescribers and Pharmacies: Mandatory Three-Month Supplies for Maintenance Medications |
| Feb. 10, 2017 |
Pharmacy Announcement: Bypass Function Added for Claims for Children under Age 18 with a Diagnosis Related to a Seizure Disorder when Prescriber is a Neurologist (Updated March 24, 2017) |
| Dec. 30, 2016 |
Pharmacy Co-Pay Increase for Brand Name Medications for Dual-Eligible Medicare Recipients |
| Dec. 30, 2016 |
Pharmacy Announcement Regarding Claims for Snake Anti-Venom |
| Nov. 7, 2016 |
Drug Use Review Board (DUR) Approves Changes to MSM Chapter 1200 Effective November 9, 2016 |
| Nov. 4, 2016 |
Pharmacy Benefit Manager Changes from CatamaranRx to OptumRx |
| Nov. 3, 2016 |
Nevada Medicaid Informational Bulletin on Medications and Services for Substance Use Disorders |
| Oct. 14, 2016 |
Drug Quantity Limits Effective October 17, 2016 |
| Sept. 12, 2016 |
Instructions for Claims for Gender Identity Disorder Hormones |
| June 3, 2016 |
Drug Quantity Limits Effective May 16, 2016 |
| May 20, 2016 |
New Prior Authorization Forms Available for Psychotropic Agents |
| May 4, 2016 |
Nevada Medicaid Will Use Federal Upper Limit Pricing Provided by Centers for Medicare & Medicaid Services for Outpatient Drugs |
| April 1, 2016 |
Update Regarding Psychotropic Medications for Children and Adolescents (Updated May 3, 2016) |
| March 1, 2016 |
Reminder to Pharmacy Providers: Document Counseling when Dispensing a Medication |
| Feb. 12, 2016 |
Narcan Nasal Spray Added to Preferred Drug List |
| Dec. 18, 2015 |
Quantity Limits for Sedative/Hypnotic Agents (Updated January 22, 2016) |
| Dec. 15, 2015 |
Psychotropic Medications for Children and Adolescents |
| Nov. 18, 2015 |
Urgent Pharmacy Announcement: Pricing Override Allowing Brand Products to Pay at Brand Price |
| Oct. 27, 2015 |
ICD-10 Diagnosis Code Reference for Drug Claims |
| Oct. 12, 2015 |
Open Provider Forums Scheduled Regarding: Pharmacy Dispensing Fee Increase and Pricing Methodology Using National Average Drug Acquisition Cost (NADAC) Files |
| Oct. 7, 2015 |
Future Changes to MSM Chapter 1200, Prescribed Drugs |
| Sept. 23, 2015 |
Pharmacy Dispensing Fee Increase and Pricing Methodology Using National Average Drug Acquisition Cost (NADAC) Files |
| Aug. 24, 2015 |
Naloxone to be Listed as Preferred on Preferred Drug List |
| Aug. 18, 2015 |
Pharmacy Dispensing Fee Increase and Pricing Methodology Using National Average Acquisition Cost (NADAC) Files |
| July 27, 2015 |
Quantity Limits for Hepatitis C Treatment Agents |
| July 21, 2015 |
Viekira Pak® Notification |
| July 1, 2015 |
Drug Use Review (DUR) Board Approves Changes to MSM Chapter 1200 Effective July 1, 2015 |
| June 25, 2015 |
State Maximum Allowable Cost (MAC) Applied to Abilify® (Updated July 13, 2015) |
| March 24, 2015 |
Pharmacy Claims Payments to be Delayed One Week |
| March 13, 2015 |
Changes for Pharmacies and Prescribers of Psychotropic Medications for Children and Adolescents Have Been Removed from the Prior Authorization Form (Updated May 1, 2015) |
| Feb. 19, 2015 |
Duplicate Dispensing Fees on Claims for Long Term Care Pharmacy Dispensing IV Medications |
| Feb. 18, 2015 |
Drug Use Review (DUR) Board Approves Changes to MSM Chapter 1200 Effective January 1, 2015 |
| Feb. 6, 2015 |
Attention Pharmacies: New Billing Instructions for Vaccine Claims when Submitted with a Non-participating Prescriber Due to Ordering, Prescribing and Referring (OPR) Practitioner Validation |
| Nov. 12, 2014 |
Use of Pharmacy Drug Discount Cards by Recipients and Retro-Eligible Refunds |
| Oct. 29, 2014 |
Update for Pharmacies: Override Period for Point-of-Sale Processing for Claims Adjudication Process to Validate Ordering, Prescribing and Referring (OPR) Practitioners Ends February 5, 2015 (Updated December 9, 2014, and January 9, 2015) |
| Oct. 28, 2014 |
Vaccines Administered by Pharmacies |
| Oct. 13, 2014 |
Copaxone® 20 mg Billing Update |
| Sept. 29, 2014 |
Hydrocodone Combination Products Change to DEA Schedule 2 |
| Aug. 25, 2014 |
Drug Use Review (DUR) Board Approves Quantity Limits Effective September 9, 2014 |
| July 16, 2014 |
Drug Use Review (DUR) Board Makes Changes to MSM Chapter 1200 Effective July 1, 2014 |
| July 14, 2014 |
340B Drug Discount Program |
| May 29, 2014 |
Payment Delay for Claims for Newly Eligible/Childless Adults |
| Apr. 11, 2014 |
URGENT: Pharmacy Claims Payments to be Delayed One Week |
| Mar. 26, 2014 |
Quantity Limit for Promethazine with Codeine Cough Syrup |
| Feb. 12, 2014 |
Prescription Co-pay Increases for Dual-eligible Recipients |
| Feb. 4, 2014 |
Billing Instruction for Benzodiazepines and Barbiturates for Dual-Eligible Recipients |
| Jan. 7, 2014 |
Policy Reminders for Covered and Non-covered Medication Process for Hospice Recipients |
| Aug. 16, 2013 |
Ritalin LA® Reimbursed at Available Wholesale Acquisition Cost (WAC) |
| Aug. 9, 2013 |
Actual Acquisition Cost (AAC) for Pharmacy Products That Do Not Have Other Pricing on File |
| July 17, 2013 |
Recipient's Date of Birth to be Required on Pharmacy Claims |
| July 16, 2013 |
Vaccine/Immunization Information for Pharmacies |
| Jan. 4, 2013 |
Reimbursement for Secondary Claims for Medicare Part B Covered Drugs |
| May 2, 2012 |
Pharmacist-Administered Adult and Childhood Immunizations Covered by Nevada Medicaid and Nevada Check Up |
| Apr. 25, 2012 |
FDA Acetaminophen Dosage Announcement |
| Mar. 15, 2012 |
EDI Announcement: March 31, 2012, End Date for Dual Use of NCPDP 5.1/D.0 and Extension of Dual Use for 4010/5010 Formats until June 30, 2012 |
| Feb. 2, 2012 |
NCPDP D.0 Payer Sheet for Pharmacy Providers |
| Dec. 16, 2011 |
EDI Announcement: Nevada Medicaid Dual Use for 5010 and D.0 Formats |
| Dec. 14, 2011 |
NCPDP D.0 Testing Instructions (Updated Dec. 16, 2011) |
| Dec. 5, 2011 |
Specifications for NCPDP, v 5.1 |
| Dec. 18, 2008 |
Prescription Origin Code Instructions Updated for 2009 |
| Dec. 17, 2008 |
Annual Co-Payment Increase for Medicare Part D/Medicaid Dual-Eligible Recipients |
| May 15, 2008 |
NPI Reminder: Use Prescriber’s NPI on Pharmacy Claims |
| Mar. 27, 2008 |
DHCFP Issues Guidance Regarding Tamper-Resistant Prescription Pads |
| Mar. 12, 2008 |
Revised Tamper-Resistant Prescription Pads and Prescription Origin Code Notification |
| Jan. 2, 2007 |
2007 Co-Payment Increase for Medicare Part D/Medicaid Dual-Eligible Recipients |
| Nov. 8, 2006 |
Nevada Prescriber List Posted Online |
| July 10, 2006 |
Billing Notice for Medicaid Recipients with Medicare Part B and/or Part D |
| June 14, 2006 |
$2/$5 Co-Payment Claims for Medicare Part D/Medicaid Recipients |
| June 2, 2006 |
Tolerances Modified for Controlled Substance Refills |
| May 10, 2006 |
Revised Co-Payment Billing Instructions |
| Feb. 21, 2006 |
Co-Payment Claims for Medicare Part D / Medicaid Recipients
Co-Payment Functionality is Now Available |
| Jan. 25, 2006 |
Billing Instructions for Part D Dual Eligible Recipients |
| Jan. 24, 2005 |
Co-Payments for Medicare Part D / Medicaid Dual Eligibles |
| Dec. 20, 2005 |
Medicare Part D Prescription Billing Information |
| Dec. 16, 2005 |
Upcoming Nevada Medicaid Changes |
| Feb. 25, 2005 |
Multi-ingredient Compound Claims, Partial Fill Functionality & Provider Training |
